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Background: Coronary artery disease (CAD) is the leading cause of mortality and morbidity in 
the United States (US), and South Asian immigrants (SAIs) have a higher risk of CAD compared 
to Caucasians. Traditional risk factors may not completely explain high risk, and some of the 
unknown risk factors need to be explored. This short review is mainly focused on the possible 
role of dysfunctional high-density lipoprotein (HDL) in causing CAD and presents an overview 
of available literature on dysfunctional HDL.
Discussion: The conventional risk factors, insulin resistance parameters, and metabolic 
syndrome, although important in predicting CAD risk, may not sufﬁ  ciently predict risk in 
SAIs. HDL has antioxidant, antiinﬂ  ammatory, and antithrombotic properties that contribute 
to its function as an antiatherogenic agent. Recent Caucasian studies have shown HDL is not 
only ineffective as an antioxidant but, paradoxically, appears to be prooxidant, and has been 
found to be associated with CAD. Several causes have been hypothesized for HDL to become 
dysfunctional, including Apo lipoprotein A-I (Apo A-I) polymorphisms. New risk factors and 
markers like dysfunctional HDL and genetic polymorphisms may be associated with CAD.
Conclusions: More research is required in SAIs to explore associations with CAD and to 
enhance early detection and prevention of CAD in this high risk group.
Keywords: South Asian immigrants, coronary heart disease, cardiovascular risk, high-density 
lipoprotein
Coronary artery disease in South Asians: what 
is known and what remains to be known
Among cardiovascular diseases, coronary artery disease (CAD) is the leading cause 
of death in the United States (US), and certain populations, such as South Asians, 
African Americans, and Hispanics, carry a disproportionately larger burden of CAD 
(Uppaluri 2002; Nordlie et al 2005; Joshi et al 2007). The mortality rates from CAD 
in South Asians are reported to be two to three times higher than those for Caucasians, 
irrespective of gender, religion, social class, dietary practices or country of residence 
(Enas et al 1992; Joshi et al 2007). This higher prevalence is seen in South Asian 
immigrants (SAIs) in the US as well as in those living in India, and rates are similar 
among vegetarians and nonvegetarians (Enas et al 1992, 1996; Mohan et al 2001; 
Goyal and Yusuf 2006; Joshi et al 2007). South Asian Indian women in California 
have the highest death rate from CAD in the United States, higher than Caucasians, 
Blacks, Hispanics, and Native Americans (Klastsy et al 1994). Speciﬁ  cally, 33% of 
all deaths among Indian women are due to CAD compared with 11% among Japanese, 
16% among Chinese, and 20% among Hispanics, Blacks, and Caucasians. In Cali-
fornia, SAIs have the highest rate of hospitalization for CAD, and Chinese have the 
lowest rate. The high rates of CAD among SAIs are not limited to the US and appear Vascular Health and Risk Management 2008:4(5) 954
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to be part of a global phenomenon (Bhopal 2002). Further, 
CAD risk factors are present in South Asians at a younger 
age compared to other populations, resulting in CAD at a 
younger age than in other populations (joshi et al 2007). 
The reasons for early development of CAD risk factors at a 
relatively young age in SAIs are still unclear.
More than 3.6 million South Asians live in the US, and 
although this group represents the second fastest growing Asian 
immigrant population, little is known regarding their increased 
risk for CAD (Uppaluri 2002). Because the population is scat-
tered across the nation, it has been difﬁ  cult to fully study the 
problem and to raise awareness within communities. There 
has been much speculation about what causes the increased 
occurrence of and mortality from CAD in SAIs. Not uniform 
groups, South Asians include ethnic subgroups with different 
cultures and practices, and the prevalence of recognized risk 
factors for CAD varies among the subgroups (Anand et al 
2000; Bhopal 2002; Bhatnagar et al 2005; Goyal and Yusuf 
2006). As a whole, however, South Asians and SAIs have a 
much higher prevalence of diabetes, insulin resistance, central 
obesity, dyslipidemias (lower high-density lipoprotein [HDL], 
increased lipoprotein [a], higher triglycerides), increased throm-
botic tendency (increased plasminogen activator inhibitor-1 
and decreased tissue plasminogen activator levels), decreased 
levels of physical activity, and lower birth weights, commonly 
known as “fetal origins hypothesis syndrome” (Forouhi and 
McKeigue 1997; Anand et al 2000; Grundy 2002; Bhatnagar 
et al 2005; Goyal and Yusuf 2006; Joshi et al 2007).
The higher CAD risk in South Asians may be related to a 
higher prevalence of metabolic syndrome which has become 
increasingly common among SAIs (Grundy 2002; Forouhi 
and McKeigue 1997; Forouhi and Sattar 2006) as compared 
to other populations (Figure 1). The syndrome is characterized 
by increased abdominal obesity, atherogenic dyslipidemias, 
high blood pressure, insulin resistance, glucose intolerance, 
prothrombotic state, and pro-inﬂ  ammatory state. However, 
even taking these differences into account, classical risk fac-
tors may not fully explain the increased risk for CAD in South 
Asians (Forouhi and McKeigue 1997; Grundy 2002; Forouhi 
and Sattar 2006; Joshi et al 2007).
The CAD rates in the US, Australia, Canada, France, 
Japan, and Finland (Peterson et al 2004) have declined to 
half over the past 30 years. These vast reductions in CAD 
mortality are generally attributed to nationwide changes 
in speciﬁ  c risk factors that were identiﬁ  ed through epide-
miological research and addressed through population-based 
interventions (McGovern et al 1996; Luepker et al 2006; 
Kottke et al 2006). Reduction in risk factors explains most 
of the decline with modest contributions from advances in 
treatment (SSSG 1994; Shepherd et al 1995; Sacks et al 1996; 
Downs et al 1998; HPS 2002). Ironically, during this time, the 
CAD rates doubled in SAIs, and the impact of risk factors and 
genetic susceptibility appears to be greater in this population 
compared with others, making SAIs a high-risk group (Enas 
2000). Migration is an important factor in determining the 
increased risk of CAD; however, other migrating populations 
(eg, Afro-Caribbean) do not have an increased risk of CAD 
compared with the indigenous population (Williams 1995). 
Thus, other speciﬁ  c factors must apply to SAIs.
Dyslipidemias in South Asians
Among numerous genetic and lifestyle parameters, 
dyslipidemias are one of the most prominent risk factors for 
CAD. Epidemiological studies have identiﬁ  ed low-density 
lipoprotein (LDL) and HDL as independent risk factors that 
modulate CAD risk (Gordon et al 1989). Though the primary 
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Figure 1 Age-standardized prevalence of metabolic syndrome deﬁ  ned by NCEP ATP II criteria.Vascular Health and Risk Management 2008:4(5) 955
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goal is to reduce LDL levels, however HDL cholesterol 
levels are among the most predictive risk factors for CAD 
(Gordon et al 1989; Tulenko and Sumner 2002). A growing 
body of experimental evidence suggests that augmenting the 
levels or function of HDL and its apolipoproteins can have 
major vascular protective effects ranging from prevention 
to stabilization and regression, independent of total or non-
HDL cholesterol levels (SSSG 1994; Shephered et al 1995; 
Sacks et al 1996; Downs et al 1998; HPS 2002). Recent 
clinical trials have stimulated tremendous interest in the 
structure, function, and therapeutic potentials of HDL. The 
National Cholesterol Educational Program Adult Treatment 
Panel III (NCEP ATP III) guidelines clearly deﬁ  ne an HDL 
level of 40 mg/dl as an independent risk factor for CAD, 
and low HDL is often present in high-risk patients with 
CAD (NCEP ATP III 2001). Although an inverse relation-
ship between HDL and risk of acute myocardial infarction is 
highly signiﬁ  cant, the relationship is far from perfect.
The common pattern of dyslipidemias seen in SAIs rela-
tive to other populations is shown in Table 1 (Anand et al 
2003). SAIs tend to have higher triglyceride levels, lower 
HDL levels, and higher lipoprotein a (Lpa) levels. However, 
a few recent studies on SAIs in the US showed that the aver-
age HDL level in both men and women was either normal or 
high (Hoogeveen et al 2001; Kalhan et al 2001). Whether this 
difference in HDL level is due to differences in migration, 
physical activity, gene-environment interactions, or other 
unknown factors is not known.
Based on known ethnic differences in risk prediction, 
the Framingham prediction model accurately predicts the 
CAD risk among Caucasians and blacks living in the United 
States. For Americans of Japanese and Hispanic descent and 
for Native Americans, the Framingham model overestimates 
CAD risk. For SAIs, the Framingham model underestimates 
CAD risk by greater than 100% (D’Agostino et al 2001; 
Bhopal et al 2005; Forouhi and Sattar 2006). Total cholesterol 
and LDL levels are correlated with the extent and severity 
of CAD in SAIs as in Caucasians, but at any given total 
cholesterol or LDL level, SAIs have a greater CAD risk 
than Caucasians (D’Agostino et al 2001; Bhopal et al 2005; 
Forouhi and Sattar 2006). Therefore, SAIs with dyslipid-
emias should be treated as the same level of importance as 
if they had a CAD risk equivalent to patients with diabetes 
or heart disease.
Over the past decade, lowering LDL levels has been 
the major target in cardiovascular protection strategies and 
clinical trials have clearly established that reductions in LDL 
are associated with a 30%–45% reduction in clinical events 
(SSSG 1994; Shepherd et al 1995; Sacks et al 1996; Downs 
et al 1998; HPS 2002). However, despite low LDL and 
normal HDL levels, many patients continue to have cardiac 
events. One can calculate from the published data (Castelli 
et al 1986) that 44% of the CAD clinical events occurred 
in men with HDL levels greater than 40 mg/dl and 43% in 
women with HDL levels greater than 50 mg/dl. Because a 
signiﬁ  cant number of CAD events occur in patients with 
normal LDL and HDL levels, there has been a continuing 
search for markers with better predictive value.
HDL role in CAD
Lipoproteins are complexes of proteins, phospholipids, 
and cholesterol. HDL is the smallest and densest of the 
lipoproteins because of its high protein content. Proteins 
make up about 50% of its mass and apolipoprotein A-I 
(Apo A-I) accounts for 70% of that protein component 
(Gordon 1989).
Apo A-I is a 243 amino acid protein synthesized in the 
liver (70%) and intestine (30%) and secreted into the serum 
in a lipid-free state (Tulenko and Sumner 2002). Individual 
Apo A-I molecules associate with other Apo A-I molecules, 
membrane phospholipids, and cholesterol to form lipid-poor 
pre-β-HDL. Lipid-poor HDL assumes a double-belt-like 
structure which becomes spherical with maturation and addi-
tion of cholesterol (Tulenko and Sumner 2002).
Lipid-poor β-HDL is able to take up cholesterol from 
artery wall macrophages via the ATP-binding cassette A-1 
Table 1 Dyslipidemias in South Asian immigrants relative to other populations (Anand et al 2000) 
Factor †South Asian †European †Chinese †p
Total cholesterol (mg/dl) 211.77 (81.90) 184.86 (81.90) 183.69 (81.90) 0.0001
LDL (mg/dl) 128.70 (35.10) 123.63 (31.20) 122.46 (31.20) 0.03
HDL (mg/dl) 38.56 (11.70) 46.41 (11.70) 46.41 (11.70) 0.0001
Triglycerides (mg/dl) 174.44 (115.70) 145.96 (115.70) 158.42 (115.70) 0.005
Lipoprotein (a) (g/L)‡ 0.0293 (0.018) 0.0259 (0.0119) 0.0259 (0.0119) 0.001
Abbreviations: LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Notes: †mean (SD), ‡Natural Log.Vascular Health and Risk Management 2008:4(5) 956
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(ABCA-1) receptor (Gordon 1989). Cholesterol is transferred 
into lipid-poor HDL and is then esteriﬁ  ed by the enzyme leci-
thin-cholesterol acyltransferase. As cholesterol is esteriﬁ  ed 
it is packaged into the core of the HDL leading to formation 
of the mature spherical lipoprotein.
Mature spherical HDL can then unload its cholesterol by 
2 main mechanisms. Transfer of cholesterol back to the liver 
is facilitated by interaction with the scavenger receptor-B1 
(SR-B1) receptor on hepatocytes and leads to formation of 
bile and secretion into the gut. Alternatively, cholesterol can 
be transferred from mature HDL to LDL or very-low-density 
lipoprotein (VLDL), a process dependent on cholesteryl 
ester transfer protein (CETP). This leads to a recycling of 
cholesterol, potentially back into the artery wall (Gordon 
1989; Tulenko and Sumner 2002).
HDL has antioxidant, antiinﬂ  ammatory, and antithrom-
botic properties that contribute to its function as an antiath-
erogenic agent. Although our understanding of how HDL 
protects against CAD is still incomplete, evidence supports 
at least three major athero-protective mechanisms of HDL.
1.  HDL is an integral component of the reverse cholesterol 
transport process, functioning as a carrier of excess cel-
lular cholesterol from peripheral tissues to the liver, where 
it is excreted from the body as bile acids and cholesterol. 
More speciﬁ  cally, HDL mediates efﬂ  ux of cholesterol 
from cholesterol-loaded macrophages by passive dif-
fusion, through scavenger receptor B1 (SR B1), and, 
most signiﬁ  cantly, via the protein Apo A-I as mentioned 
above (Williams et al 1999; Yancey et al 2003). Apo A-I 
functions through an ATP-binding cassette transporter 
A1 (ABCA1) in the vessel wall, where it accepts free 
cholesterol, forming pre-beta HDL that matures after 
esteriﬁ  cation to cholesteryl esters (CE) and then by 
lecithin-cholesterol acyltransferase to alpha migrating 
HDL (Takahashi and Smith 1999; Remaley et al 2000; 
Mackness et al 2002).
2.  A series of antioxidant enzymes which protect LDL from 
oxidation are associated with HDL. Oxidized lipids are 
transferred to HDL from LDL and are hydrolyzed by 
HDL-associated PON1, LCAT, and platelet-activating 
factor (PAF) acetylhydrolase enzymes (Navab et al 2001; 
Mackness et al 2002; Marathe et al 2002). The activities 
of these enzymes destroy oxidized lipids and also inhibit 
their formation. Removing the oxidized lipids initiates a 
positive feedback loop that results in further activation 
of the enzymes and further destruction of the oxidized 
lipids. In addition, Apo A-I reduces lipid peroxides within 
LDL, independent of PON1 (Marathe et al 2002).
3.  HDL may protect against CAD by selectively decreasing 
endothelial cell adhesion molecules, which facilitate the 
binding of mononuclear cells to the vessel wall and pro-
mote lesion development (Barter et al 2002).
Evidence that HDL may not be 
protective: dysfunctional HDL
According to several recent studies, in patients with CAD, 
HDL is not only ineffective as an antioxidant but, paradoxi-
cally, appears to be pro-oxidant, promoting LDL oxidation 
and monocytes chemotactic activity in the human artery wall 
as well as increasing HDL lipid hydroperoxides, as assessed 
by its lipid peroxide content (Navab et al 2000; Fogelman 
2004; Ansell et al 2005, 2006). In addition, HDL from 
patients with a history of CAD enhances the oxidation of LDL 
and of phospholipids in LDL (Ansell et al 2006; Navab et al 
2006). This pro-inﬂ  ammatory HDL, which is dysfunctional, 
accumulates oxidants that inhibit HDL-associated antioxidant 
enzymes, render Apo A-I unable to promote ABCA1 medi-
ated cholesterol efﬂ  ux, and promotes the formation of LDL-
derived oxidized lipids (Fogelman 2004) (Figure 2). The 
mechanisms underlying this phenomenon are not completely 
understood. One of the hypothesized mechanisms involves 
myeloperoxidase (Zheng et al 2004). Apo A-I is targeted by 
myeloperoxidase, and, when oxidized and nitrated, impairs 
ABCA1-dependent cholesterol efﬂ  ux. Furthermore, expos-
ing HDL or Apo A-I to myeloperoxidase almost entirely 
prevents ABCA1-dependent reverse cholesterol transport 
(Fogelman 2004). It has been hypothesized that a certain 
variant of Apo A-I is susceptible to oxidation and nitration 
(Navab et al 2004).
The diagnosis of dysfunctional HDL has historically been 
made with a cell-based assay that requires endothelial cells, 
smooth muscle cells, and monocytes. However, the use of 
a cell-based assay is not practical for large-scale studies. 
Recently, a cell-free assay was developed to detect HDL that 
is dysfunctional in preventing the formation or inactivation 
of oxidized phospholipids (Navab et al 2001; Ansell et al 
2003, 2007). This is a rapid test for HDL function that does 
not require cells and gives results highly comparable to those 
of the previously described cell-based assay (Navab et al 
2001). Using this assay, investigators determined that HDL 
from patients with documented CAD was pro-inﬂ  ammatory 
(dysfunctional), while HDL from normal subjects was antiin-
ﬂ  ammatory. These patients had normal levels of blood lipids, 
had no major risk factors for CAD, and therefore, would 
not have been predicted to be at risk for atherosclerosis by 
conventional risk factor analysis. In short, the new cell-free Vascular Health and Risk Management 2008:4(5) 957
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assay has the potential to allow wide-spread testing for HDL 
that is dysfunctional and identiﬁ  cation of individuals at risk 
for CAD.
The inﬂ  ammatory/antiinﬂ  ammatory properties of HDL can 
be determined by calculating HDL inﬂ  ammatory index (Navab 
et al 2001; Ansell et al 2003, 2007). This index is calculated 
by normalizing the cell-free assay values obtained for a stan-
dard LDL alone to 1.0. Using this normalization procedure, 
a test HDL is classiﬁ  ed as proinﬂ  ammatory (dysfunctional) 
when addition of the test HDL along with an LDL standard 
to the assay results in a normalized value of 1.0 or greater. 
Conversely, a value less than 1.0 classiﬁ  es the test HDL as 
antiinﬂ  ammatory. A small study of  20 Caucasian subjects with 
elevated HDL showed an inﬂ  ammatory index of 1.28 ± 0.29 
in CAD patients compared to 0.35 ± 0.29 in healthy subjects, 
clearly separating patients from controls (Ansel et al 2003).
Proinﬂ  ammatory (dysfunctional) 
HDL in SAIs?
Current data indicates that a 1% increase in HDL serum 
concentration can decrease cardiovascular risk by 2%–3%, 
independent of LDL levels (Gordon et al 1989). However, 
HDL can have this protective effect only if it is functional. 
The incidence of prooxidant or proinflammatory HDL 
(dysfunctional HDL) in SAIs is not known.
A small study done on SAIs showed inﬂ  ammatory index 
values of 1.00 in 50% (95% CI 0.8772–1.4333) with 
normal HDL suggesting proinﬂ  ammatory or dysfunctional 
HDL (Dodani et al 2008b). In addition, proinﬂ  ammatory 
HDL (1.00) was associated with CAD, using IMT 
values 0.80 mm as surrogate marker for CAD (p = 0.04). 
The mean HDL inﬂ  ammatory Index was 0.8772 in the group 
with CAD and 0.6269 in the group without CAD. Further work 
is needed to understand the relationship of dysfunctional HDL 
with HDL levels.
Given that animal and small-scale human studies sug-
gest that measures of the quality and functionality of HDL 
can provide an improved means of identifying subjects at 
increased risk for atherosclerotic events, compared with the 
current practice of only measuring the level of  HDL (NCEP 
ATP III 2001), the level of dysfunctional HDL and its asso-
ciation with CAD in SAIs needs to be explored in bigger 
studies. Given the results of small studies, we can hypothesize 
that SAIs have a high prevalence of dysfunctional HDL and 
that this could be related to their excessive risk of CAD. We 
are currently funded by the National Institute of Health ( NIH) 
to study association of dysfunctional HDL with CAD in SAIs. 
Similarly, SAIs carry an increased prevalence of metabolic 
syndrome and diabetes (subclinical chronic inﬂ  ammation) 
as compared to other groups, therefore, we predict that this 
population has increased dysfunctional HDL and is related 
to coronary events (Grundy 2002; Tillin et al 2005; Forouhi 
and Sattar 2006). Patients with metabolic syndrome tend 
to have dysfunctional HDL (proinﬂ  ammatory HDL) more 
often than controls (Watson et al 2007). Identiﬁ  cation of 
dysfunctional HDL and its association with carotid IMT and 
ab
Myeloperoxidase
Nitrotyrosine
Chlortyrosine
Anti-inflammatory Proinflammatory
Apo A-I Apo A-I
Paraoxonase,
other factors
Proinflammatory
factors, other factors
Figure 2 Model of bidirectional conversion of high-density lipoprotein from antiinﬂ  ammatory (a) to proinﬂ  ammatory (b). Copyright © 2004. Reproduced with permission 
from Fogelman AM. 2004.   When good cholesterol goes bad. Nat Med, 10:902–3.
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metabolic syndrome in SAIs will help to identify high-risk 
individuals; high risk that cannot be explained by traditional 
risk factors. Patients found to have dysfunctional HDL and 
no other CAD risk factors can be targeted for early lipid-
lowering treatment which has been shown to improve HDL 
antiinﬂ  ammatory function (Ansell et al 2003, 2007; Kumar 
and Reynolds 2005). However, weather measures of dys-
functional HDL are superior to other indirect markers like 
total cholesterol/HDL ratio, Apolipoprotein B/Apo A-I ratio 
requires more research.
Apo A-I and gene polymorphisms
Apo A-I (APOAI gene, Apo A-I protein) is the major protein 
of HDL and consists of a 243 amino acid-long peptide, 
synthesized mainly in the liver and to some extent in the 
small intestine. The inverse relationship between HDL 
plasma levels and CAD has been attributed to the role that 
HDL and its major constituent Apo A-I play in reverse cho-
lesterol transport (RCT). The efﬁ  ciency of RCT depends on 
the speciﬁ  c ability of Apo A-I to promote cellular cholesterol 
efﬂ  ux, bind lipids, activate lecithin: cholesterol acyltrans-
ferase (LCAT), and form mature HDL that interacts with 
speciﬁ  c receptors and lipid transfer proteins (Stampfer et al 
1991; Karathanasis et al 1985; Frank and Marcel 2000). The 
APOAI gene is present along with the APOC3 and APOA4 
genes, on chromosome 11(11q23.3-qter). It has also been 
shown that the A allele of the APOAI gene contributes to 
the severity of CAD and low levels of HDL among Northern 
Indians (Chhabra et al 2005).
Epidemiological studies have shown that HDL and Apo 
A-I levels are inversely correlated with the risk of devel-
oping CAD (Jadhav and Kadam 2004; Navab et al 2005; 
Chhabra et al 2005). Although various factors such as genetic 
variations, diet, exercise, alcohol, smoking, hormones, and 
certain drugs can signiﬁ  cantly inﬂ  uence the levels of HDL 
and Apo A-I (Lusis et al 2004), family and twin studies 
have demonstrated a strong genetic heritability, accounting 
for up to 66% of the variability of HDL and Apo A-I levels 
(Calbresi et al 1997; Jadhav and Kadam 2004; Chhabra 
et al 2005). Furthermore, 40%–60% of the inter-individual 
variation in HDL concentrations is controlled at the genetic 
level (Chhabra et al 2005) and the strong positive correlation 
between plasma levels of Apo A-I and HDL suggests that 
Apo A-I gene polymorphisms may be linked to variability 
in HDL levels as well as to dysfunction (Chhabra et al 2005; 
Navab et al 2005).
More than 40 mutations in Apo A-I have been iden-
tified in several ethnic populations (Moll et al 1989; 
Koistinen et al 1994; Calabresi and Franceschini 1997; 
Jadhav and Kadam 2004; Lusis et al 2004; Chhabra et al 
2005), each producing differing HDL activity and levels. Apo 
A-I gene mutations are separated into three classes. Class I 
includes mutations that prevent the formation of Apo A-I; 
class II defects lead to expression of a truncated Apo A-I 
protein; and class III defects result in an altered functional 
state of Apo A-I. Not surprisingly, class I mutations are asso-
ciated with CAD, xanthomatosis, and corneal opaciﬁ  cations, 
whereas class II mutations exhibit variable phenotypes (Moll 
et al 1989; Koistinen et al 1994; Calabresi and Franceschini 
1997; Frank and Marcel 2000; Lusis et al 2000). Mutations 
affecting the structure   of Apo A-I (nonsense mutations 
with premature stop codons or large genomic deletions) 
result in an absence of Apo A-I in plasma and a marked 
reduction in HDL levels (Moll et al 1989). Interestingly, of 
the 12 mutations that truncate Apo A-I, not all are associ-
ated with CAD. Further, several point mutations have been 
identiﬁ  ed (Moll et al 1989; Koistinen et al 1994; Calabresi 
and Franceschini 1997; Frank and Marcel 2000), and one in 
particular is associated with low levels of HDL but not with 
an increased CAD risk and is, instead, associated with a 
reduction in CAD risk (Boekholdt et al 2006). This Apo A-I 
mutation is called Apo A-I milano (Apo A-IArg 173 Cys).
Apo A-I polymorphisms in SAIs
A majority of the studies on Apo A-I polymorphisms and 
their association with HDL level and CAD have been carried 
out in Caucasian and other populations. The association of 
Apo A-I gene polymorphisms with carotid IMT as a sur-
rogate marker for atherosclerosis has been examined, but 
not fully. For example, Apo A-I (L178P) was found to be 
associated with high IMT measurements (p  0.001) in a 
European population, however due to the small sample size, 
results can not be generalized (Pulkkinen et al 2000). Simi-
larly, Apo A-I/C-III/A-IV SstI polymorphism was found to 
be associated with high carotid IMT measurements in a study 
of a young Finnish population (Wang et al 1996). However, 
the role of Apo A-I polymorphisms in individuals with 
metabolic syndrome and its association with dysfunctional 
HDL has not yet been fully studied. A few studies have 
examined Apo A-I polymorphisms in native populations 
of South Asians from India, however, to our knowledge, 
no study has examined Apo A-I polymorphisms in SAIs 
and its association with dysfunctional HDL, IMT, or CAD. 
Polymorphisms in Apo A-I and other lipid metabolism-
related genes have been suggested to be clinically useful 
in assessing an individual’s risk for cardiovascular disease Vascular Health and Risk Management 2008:4(5) 959
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and in conducting genetic-epidemiological evaluations 
(Perez-Mendez et al 2000).
Given that SAIs are signiﬁ  cantly under-represented in 
major clinical trials, evidence-based management strategies 
for treatment and prevention of CAD speciﬁ  cally in this 
population is seriously lacking. A literature search for Apo 
A-I gene mutations in South Asian populations yielded a 
small study that showed polymorphisms in the Apo lipopro-
tein C-III promoter gene that were associated with features of 
metabolic syndrome in South Asian Indians; the relationship 
of these polymorphisms to CAD was not examined (Hovingh 
et al 2004; Guettier 2005; Islam et al 2005). A recent small 
study conducted on Pakistanis suggested that the promoter 
region of the Apo A-I gene may play a role in determining 
blood pressure (Sadaf et al 2002), however, due to insufﬁ  -
cient power, these results cannot be generalized. Chhabra and 
colleagues (2005) found a correlation between the expression 
of the Apo A-I G-75A polymorphism in northern Indians, the 
severity of CAD, and low levels of HDL; however this study 
was restricted to one ethnic group and relationship was not 
examined in other ethnic groups. Studies have shown that 
South Indians carry more CAD risk as compared to North 
Indians (Hoogeveen 2001).
In a small study on SAIs, six novel polymorphisms were 
identiﬁ  ed, one of which, G4 (C938T), was signiﬁ  cantly asso-
ciated with low (40 mg/dl) HDL levels (p = 0.03) (Dodani 
et al 2008a). Further research is required to explore Apo A-I 
polymorphisms in SAIs and correlate possible associations 
with dysfunctional HDL and CAD. Moreover, it may lead 
to screening tests that will allow early detection and control 
of the developing CAD. Also these tests may lead to the 
development of gene therapy mechanisms useful in the treat-
ment of CAD in SAIs.
Conclusion
People of South Asian origin constitute a large, visible minor-
ity in the United States and are known to be at heightened 
risk for premature CAD. Conventional risk factors clearly 
confer risk in South Asians but do not adequately explain 
their excess risk compared with other populations. New risk 
factors and markers like dysfunctional HDL, genetic poly-
morphism though shown to be linked with CAD; however 
greater research is required in South Asians. The rates of 
CAD have accelerated dramatically amongst South Asians, 
driven to an important extent by the atherogenic dyslipidemia 
and type 2 diabetes that have become so common amongst 
them. South Asians may have a genetic predisposition to 
CAD; however, environmental, nutritional, and lifestyle 
factors may also be responsible. South Asians have a much 
higher prevalence of metabolic syndrome, diabetes, insulin 
resistance (and resultant hyperinsulinemia), central obesity, 
dyslipidemias (lower HDL, increased lipoprotein[a], higher 
triglyceride levels), increased thrombotic tendency (increased 
plasminogen activator inhibitor-1 and decreased tissue 
plasminogen activator levels), decreased levels of physical 
activity, and low birth weights (“fetal origins hypothesis”). 
In addition, the dietary indiscretions and sedentary lifestyle 
practiced by most South Asians puts them at a higher risk. 
A multidisciplinary approach involving the population at 
risk, healthcare personnel, and the government is required 
to diminish the incidence.
The key to combating the increasing incidence of CAD 
among South Asians is the treatment of known risk factors 
through both an individual-based as well as a population-
based approach aimed at comprehensive risk factor reduction. 
In addition, further research is needed to discover new risk 
factors like dysfunctional HDL that can be responsible for an 
excess CAD risk, not explained by conventional risk factors.
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